1Reinartz S,Boerner H,Koehler S,et al.Evaluation of immunological responses in patients with ovarian cancer treated with the anti-idiotype vaccine ACA125 by determination of intracellular cytokines-a preliminary report.Hybridoma,1999,18(1):41-45.
2Wagner U,Kohler S,Reinartz S,et al.Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res,2001, 7(5):1 154-1 162.
3Lin CW, Lee JY, Tsao YP, et al. Oral vaccination with recombinant Listeria monocytogenes expressing human papillomavirus type 16 E7 can cause tumor growth in mice to regress.Int J Cancer,2002,102(6):629-637.
4Kaufmann AM, Stern PL, Rankin EM,et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus HPV-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.Clin Cancer Res,2002,8(12):3 676-3 685.
5Eggert AA,Schreurs MW,Boerman OC,et al.Biodistri-bution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res,1999,59(14):3 340-3 345.
6Ribas A,Bui LA,Butterfield LH,et al.Antitumor prote-ction using murine dendritic cell pulsed with acid-eluted peptides from in vivo grown tumors of different immunogencities.Anticancer Res, 1999, 19(2A): 1 165-1 170.
7Pierrefite-Carle V, Baque P, Gavelli A, et al. Cytosine deaminase/5-fluorocytosine-based vaccination against liver tumors: evidence of distant bystander effect. J Natl Cancer Inst,1999,91(23):2 014-2 019.
8Al-Hendy A,Magliocco AM,Al-Tweigeri T,et al.Ovari-an cancer gene therapy: repeated treatment with thymidine kinase in an adenovirus vector and ganciclovir improves survival in a novel immunocompetent murine model. Am J Obstet Gynecol, 2000,182(3):553-559.
9Vandier D, Calvez V, Massade L, et al. Transactivation of the metallothionein promoter in cisplatin-resistant cancer cells: a specific gene therapy strategy.J Natl Cancer Inst, 2000,92(8):642-647.
10Hasenburg A,Fischer DC,Tong XW,et al.Histologic and immunohistochemical analysis of tissue response to adenovirus-mediated herpes simplex thymidine kinase gene therapy of ovarian cancer. Int J Gynecol Cancer, 2002, 12(1):66-73.
二级参考文献9
1Harris A L，Breast Cancer Res Treat，1996年，38卷，1期，97页
2Wang CY,Cusack JC,Liu R,et al. Control of inducible chem- oresistence: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κappaB. Nat Med,1999,5:412-417.
3Otsuka G, Nagaya T,Saito K, et al. Inhibition of nuclear factor-κappaB activation confers sensitivity to tumor necrosis factor-alpha by immpairment of cell cycle progresion in human glioma cells. Cancer Res,1999,59:4446-4452.
4Wang CY, Mayo MW, Baldwin AS,et al. TNF and cancer therapy induced apoptosis:potentiation by inhibition of NF-κappaB. Science, 1996, 274:784-787.
5Baeuerle PA, Baltimore D. NF-κappaB: ten years after. Cell, 1996, 87:13-20.
6Sumitomo M,Tachibana M,Nakashima J,et al.An essential role for nuclear factor κappaB in preventing TNF-alpha-induced cell death in prostate cancer cells. J Urol,1999,161:674-679.
7Miyamoto S, Verma IM. Rel/NF-kappaB/IkappaB story. Adv Cancer Res,1995,66:255-292.
8Perera PY, Qureshi N, Vogel SN. Paclitaxel(taxol)-induced NF-κappaB translocation in murine macrophages. Infect Immun, 1996, 64:878-884.
